Signals, Powered By EquityPandit
The US health regulator has provided its tentative approval to the Glenmark Pharmaceuticals for tablets that are used in treating overactive bladder.
Glenmark Pharmaceuticals said in a BSE filing that the company has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets, 5 mg and 10 mg.
The products of the company are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc.
